Welcome to the ePoster Viewing Panel of AICOG 2025

INTRODUCTION- Mixed connective tissue disease (MCTD) is a multisystem rheumatic disease with overlapping features of SLE, systemic sclerosis, rheumatoid arthritis, and polymyositis. MCTD in pregnancy puts women at risk of medical and obstetric complications. Maternal complications include preeclampsia , thrombocytopenia, thromboembolism events, and death. Fetal complications include prematurity , intrauterine growth restriction , and neonatal lupus , neonatal thrombocytopenia. AIMS AND OBJECTIVES- To deliver a healthy baby and a healthy mother via a multidisciplinary approach of thrombocytopenia in pregnany secondary to mixed connective tissue disorder. MATERIALS AND METHODS- Managed a case of thrombocytopenia in pregnancy at LTMGH ,SION. We present a case of 26 yr G4P3L3 at 26 wk presented with dark patches , ecchymosis, petechia , generalized weakness and myalgia with investigations suggestive of platelet count of 8000/ cmm with ANA ++ and UiRNA ++ status. Diagnosed as a case of thrombocytopenia in pregnancy secondary to Mixed Connective Tissue Disorder. RESULTS- Patient was managed through a multidisciplinary approach . Delivered at 37 wk a healthy male baby of 2.7 kg and was discharged day 35 PNC with 120000 platelet counts. CONCLUSION- Mixed Connective Tissue Disorder flares during pregnancy and is treated with steroids, combined with safe immunosuppressants, biologic agents and/or IV Immunoglobulins might be necessary. In view of life-threatening complications in mother as well as the fetus, termination is the best choice. Pre-pregnancy counselling, risk assessment and stratification, a multidisciplinary approach, tailored antenatal and postnatal management plans, an experienced high-level neonatal unit, and early recognition of flares and complications (either medical and/or obstetric), are essential cornerstones for optimizing the chance of successful outcomes for both mother and fetus.